FDA approves noninvasive Optune Pax device for advanced pancreatic cancer
Medical Xpress
February 18, 2026
The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of Optune Pax was granted to Novocure.
Verticals
healthmedical
Originally published on Medical Xpress on 2/18/2026